Scott L. Townley

Scott L. Townley

Auto-generated profile, based on publicly available information

Scott L. Townley

Flinders Health and Medical Research Institute, Flinders University, Bedford Park, Australia. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RSRaj Kumar. Shrestha
Raj Kumar. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
Solid tumors are highly reliant on lipids for energy, growth, and survival. In prostate cancer, the activity of the androgen receptor (AR) is associated with reprogramming of lipid metabolic processes. Here, we identified acyl-CoA synthetase medium chain family members 1 and 3 (ACSM1 and ACSM3) as AR-regulated mediators of prostate cancer metabolism and growth. ACSM1 and ACSM3 were upregulated in prostate tumors compared with nonmalignant tissues and other cancer types. Both enzymes enhanced proliferation and protected prostate cancer cells from death in vitro, whereas silencing ACSM3 led to reduced tumor growth in an orthotopic xenograft model. ACSM1 and ACSM3 were major regulators of the prostate cancer lipidome and enhanced energy production via fatty acid oxidation. Metabolic dysregulation caused by loss of ACSM1/3 led to mitochondrial oxidative stress, lipid peroxidation, and cell death by ferroptosis. Conversely, elevated ACSM1/3 activity enabled prostate cancer cells to survive toxic levels of medium chain fatty acids and promoted resistance to ferroptosis-inducing drugs and AR antagonists. Collectively, this study reveals a tumor-promoting function of medium chain acyl-CoA synthetases and positions ACSM1 and ACSM3 as key players in prostate cancer progression and therapy resistance. Significance: Androgen receptor–induced ACSM1 and ACSM3 mediate a metabolic pathway in prostate cancer that enables the utilization of medium chain fatty acids for energy production, blocks ferroptosis, and drives resistance to clinically approved antiandrogens.

15 July 2024
Verified
Other
Open access
PDF file
RSRaj K. Shrestha
Raj K. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
ACSM3 protein levels are elevated in prostate cancer.

15 July 2024
Verified
Other
Open access
PDF file
RSRaj K. Shrestha
Raj K. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
Effect of medium chain fatty acids on prostate cancer cells.

15 July 2024
Verified
Other
Open access
RSRaj K. Shrestha
Raj K. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
List of genes encoding enzymes with a putative role in lipid metabolism

15 July 2024
Verified
Other
Open access
PDF file
RSRaj K. Shrestha
Raj K. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
Efficacy of siRNAs targeting ACSM1 and ACSM3.

15 July 2024
Verified
Other
Open access
PDF file
RSRaj K. Shrestha
Raj K. Shrestha
ZNZeyad Nassar
Zeyad Nassar
AHAdrienne R. Hanson
Adrienne R. Hanson
RIRichard Iggo
Richard Iggo
STScott L. Townley
Scott L. Townley
LSLuke Selth
Luke Selth
Loss of ACSM1 and ACSM3 causes lipid peroxidation and oxidative stress.